Showing 8001-8010 of 8822 results for "".
- Biofrontera Files Investigational NDA for Phase 3 Trial of Ameluz for BCChttps://practicaldermatology.com/news/biofrontera-files-investigational-nda-for-phase-3-trial-of-ameluz-for-bcc/2457948/Biofrontera AG has filed an investigational new drug (IND) application with the FDA for its proposed Phase 3 study protocol to evaluate Ameluz® photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma. The IND filing is in accordance with the advice provided by F
- Acne Anxiety Dampens Teen Social Media Usehttps://practicaldermatology.com/news/acne-anxiety-curbs-teen-social-media-use/2457952/Teens with acne report a negative impact on their body image and self-esteem, and this translates into anxiety over using social media, mainly the online posting of photos, videos and "selfies." The survey was commissioned by Cutanea Life Sciences, Inc. (CLS), a U.S. b
- Almirall and Athenex Form Strategic Partnership for Treatment of AKshttps://practicaldermatology.com/news/almirall-and-athenex-form-strategic-partnership-for-treatment-of-aks/2457957/Almirall, S.A and Athenex, Inc. recently formed a partnership to further develop and commercialize KX2-391 for the treatment of actinic keratosis (AK) and other skin conditions. Subject to the terms and conditions of the license agreement, Athenex will grant to Almirall an exclusive
- Revance: RT002 Achieves 6-Month Duration in Phase 3https://practicaldermatology.com/news/revance-rt002-achieves-6-month-duration-in-phase-3/2457959/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared ge
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- New Analysis Provides Reassurance on Biosimilar Safetyhttps://practicaldermatology.com/news/new-analysis-provides-reassurance-on-biosimilar-safety/2457964/And they’re … safe. Biosimilars, which have been available in the European Union since 2006, show no substantial differences in the reporting of safety information than their originators, according to a new analysis in the
- Water Baths As Effective As Bleach Baths for Eczemahttps://practicaldermatology.com/news/water-baths-as-effective-as-bleach-baths-for-eczema/2457967/Water baths are as good as bleach baths for treating eczema, and they are safer, finds a new Northwestern Medicine study. Bleach baths can cause stinging and burning of skin, and occasionally even trigger asthma flare-ups in patients. “I don’t know if it throws the bab
- Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Executionhttps://practicaldermatology.com/news/novan-plans-to-complete-development-of-sb204-acne-candidate-via-third-party-funding-and-execution/2457981/Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Dr
- Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studieshttps://practicaldermatology.com/news/abbvies-risankizumab-performs-well-in-three-phase-three-psoriasis-studies/2457991/Top-line results from three pivotal Phase 3 clinical trials show that risankizumab, an investigational interleukin-23 (IL-23) inhibitor,
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by